BACKGROUND: The high incidence of ductal carcinoma in situ (DCIS) and variations in its treatment motivate inquiry into the comparative effectiveness of treatment options. Few such comparative effectiveness studies of DCIS, however, have been performed with detailed information on clinical and treatment attributes. METHODS: We collected detailed clinical, nonclinical, pathological, treatment, and long-term outcomes data from multiple medical records of 994 women who were diagnosed with DCIS from 1985 through 2000 in Monroe County (New York) and the Henry Ford Health System (Detroit, MI). We used ipsilateral disease-free survival models to characterize the role of treatments (surgery and radiation therapy) and margin status (positive, close [<2 mm], or negative [≥2 mm]) and logistic regression models to characterize the determinants of treatments and margin status, including the role of surgeons. All statistical tests were two-sided. RESULTS: Treatments and margin status were statistically significant and strong predictors of long-term disease-free survival, but results varied substantially by surgeon. This variation by surgeon accounted for 15%-35% of subsequent ipsilateral 5-year recurrence rates and for 13%-30% of 10-year recurrence rates. The overall differences in predicted 5-year disease-free survival rates for mastectomy (0.993), breast-conserving surgery with radiation therapy (0.945), and breast-conserving surgery without radiation therapy (0.824) were statistically significant (P(diff) < .001 for each of the differences). Similarly, each of the differences at 10 years was statistically significant (P < .001). CONCLUSIONS: Our work demonstrates the contributions of treatments and margin status to long-term ipsilateral disease-free survival and the link between surgeons and these key measures of care. Although variation by surgeon could be generated by patients' preferences, the extent of variation and its contribution to long-term health outcomes are troubling. Further work is required to determine why women with positive margins receive no additional treatment and why margin status and receipt of radiation therapy vary by surgeon.
BACKGROUND: The high incidence of ductal carcinoma in situ (DCIS) and variations in its treatment motivate inquiry into the comparative effectiveness of treatment options. Few such comparative effectiveness studies of DCIS, however, have been performed with detailed information on clinical and treatment attributes. METHODS: We collected detailed clinical, nonclinical, pathological, treatment, and long-term outcomes data from multiple medical records of 994 women who were diagnosed with DCIS from 1985 through 2000 in Monroe County (New York) and the Henry Ford Health System (Detroit, MI). We used ipsilateral disease-free survival models to characterize the role of treatments (surgery and radiation therapy) and margin status (positive, close [<2 mm], or negative [≥2 mm]) and logistic regression models to characterize the determinants of treatments and margin status, including the role of surgeons. All statistical tests were two-sided. RESULTS: Treatments and margin status were statistically significant and strong predictors of long-term disease-free survival, but results varied substantially by surgeon. This variation by surgeon accounted for 15%-35% of subsequent ipsilateral 5-year recurrence rates and for 13%-30% of 10-year recurrence rates. The overall differences in predicted 5-year disease-free survival rates for mastectomy (0.993), breast-conserving surgery with radiation therapy (0.945), and breast-conserving surgery without radiation therapy (0.824) were statistically significant (P(diff) < .001 for each of the differences). Similarly, each of the differences at 10 years was statistically significant (P < .001). CONCLUSIONS: Our work demonstrates the contributions of treatments and margin status to long-term ipsilateral disease-free survival and the link between surgeons and these key measures of care. Although variation by surgeon could be generated by patients' preferences, the extent of variation and its contribution to long-term health outcomes are troubling. Further work is required to determine why women with positive margins receive no additional treatment and why margin status and receipt of radiation therapy vary by surgeon.
Authors: Sarah T Hawley; Tim P Hofer; Nancy K Janz; Angela Fagerlin; Kendra Schwartz; Lihua Liu; Dennis Deapen; Monica Morrow; Steven J Katz Journal: Med Care Date: 2006-07 Impact factor: 2.983
Authors: Nina Bijker; Philip Meijnen; Johannes L Peterse; Jan Bogaerts; Irène Van Hoorebeeck; Jean-Pierre Julien; Massimiliano Gennaro; Philippe Rouanet; Antoine Avril; Ian S Fentiman; Harry Bartelink; Emiel J Th Rutgers Journal: J Clin Oncol Date: 2006-06-26 Impact factor: 44.544
Authors: Lorie L Hughes; Molin Wang; David L Page; Robert Gray; Lawrence J Solin; Nancy E Davidson; Mary Ann Lowen; James N Ingle; Abram Recht; William C Wood Journal: J Clin Oncol Date: 2009-10-13 Impact factor: 44.544
Authors: Monica Morrow; Reshma Jagsi; Amy K Alderman; Jennifer J Griggs; Sarah T Hawley; Ann S Hamilton; John J Graff; Steven J Katz Journal: JAMA Date: 2009-10-14 Impact factor: 56.272
Authors: Sarah T Hawley; Jennifer J Griggs; Ann S Hamilton; John J Graff; Nancy K Janz; Monica Morrow; Reshma Jagsi; Barbara Salem; Steven J Katz Journal: J Natl Cancer Inst Date: 2009-08-31 Impact factor: 13.506
Authors: Heather Spencer Feigelson; Ted A James; Richard M Single; Adedayo A Onitilo; Erin J Aiello Bowles; Tom Barney; Jordan E Bakerman; Laurence E McCahill Journal: J Am Coll Surg Date: 2013-03-13 Impact factor: 6.113
Authors: Heather Taffet Gold; Melony E S Sorbero; Jennifer J Griggs; Huong T Do; Andrew W Dick Journal: Med Care Res Rev Date: 2011-05-19 Impact factor: 3.929
Authors: Azadeh Stark; Robert Stapp; Aditya Raghunathan; Xiaowei Yan; H Lester Kirchner; Jennifer Griggs; Lisa Newman; Dhananjay Chitale; Andrew Dick Journal: Breast Cancer Res Treat Date: 2011-08-27 Impact factor: 4.872
Authors: Brian L Sprague; Pamela M Vacek; Sally D Herschorn; Ted A James; Berta M Geller; Amy Trentham-Dietz; Janet L Stein; Donald L Weaver Journal: Breast Cancer Res Treat Date: 2018-11-17 Impact factor: 4.872
Authors: Megan R Haymart; Mousumi Banerjee; Di Yang; Andrew K Stewart; Gerard M Doherty; Ronald J Koenig; Jennifer J Griggs Journal: Ann Surg Date: 2013-08 Impact factor: 12.969